Phase I study of palbociclib, a cyclin‐dependent kinase 4/6 inhibitor, in Japanese patients

This phase I study in Japanese patients evaluated the safety, pharmacokinetics, and preliminary efficacy of palbociclib, a highly selective and reversible oral cyclin‐dependent kinase 4/6 inhibitor, as monotherapy for solid tumors (part 1) and combined with letrozole as first‐line treatment of postm...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamura, Kenji, Mukai, Hirofumi, Naito, Yoichi, Yonemori, Kan, Kodaira, Makoto, Tanabe, Yuko, Yamamoto, Noboru, Osera, Shozo, Sasaki, Masaoki, Mori, Yuko, Hashigaki, Satoshi, Nagasawa, Takashi, Umeyama, Yoshiko, Yoshino, Takayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4968608/
https://www.ncbi.nlm.nih.gov/pubmed/26991823
http://dx.doi.org/10.1111/cas.12932

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4968608/
https://www.ncbi.nlm.nih.gov/pubmed/26991823
http://dx.doi.org/10.1111/cas.12932

Ejemplares similares